[Newsmp] The Cancer Diseases Deliberation Committee has given its approval for AstraZeneca’s anticancer drug Tagrisso.
On March 22, the Health Insurance Review and Assessment Service (HIRA) disclosed the results of its 2nd Cancer Diseases Deliberation Committee.
During the meeting, two drugs, Tagrisso (AstraZeneca) and Darzalex (Janssen) were reviewed.
Tagrisso (ingredient: Osimertinib) obtained reimbursement expansion and standards by demonstrating efficacy and effectiveness as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
Janssen Korea’s Darzalex (ingredient: Daratumumab) applied for reimbursement expansion based on its efficacy in combination with lenalidomide and dexamethasone, bortezomib and dexamethasone, and carfilzomib and dexamethasone for multiple myeloma patients who have received one or more prior therapies but did not pass the Cancer Diseases Deliberation Committee's evaluation for all three efficacy and effects.
